Evoke Pharma Inc (EVOK) - Koefisien utang jangka dawa marang modal

Evoke Pharma Inc - logo grafis emiten EVOK

Evoke Pharma, Inc. (EVOK) generates revenue from an innovative nasal treatment for diabetic gastroparesis, whose specific application ensures customer loyalty and a steady cash flow. Meanwhile, the business is implementing eco-friendly packaging and safe synthesis methods. This price chart reflects a value of 0.01. High product margins allow the company to reduce the impact of fixed logistics and promotion costs as sales volumes grow.

Evoke Pharma Inc. (EVOK): Utang jangka dawa marang ekuitas saka 04.07.2022 nganti 27.12.2025
Produk mawa merek Evoke Pharma, Inc.

Professional capital assesses the financial stability of the issuer through its liability structure. This long-term debt-to-net assets ratio compares loans with maturities exceeding one year against the market value of equity. Rising leverage increases interest expenses, creating risks during rate hikes. For Evoke Pharma, Inc. (EVOK), this is critical when scaling sales of the Gimoti spray. Low reliance on borrowed funds confirms the asset's reliability.